ReviewAnnals of translational medicine2020
Vasopressors in septic shock: which, when, and how much?
Review in Annals of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07716956 (Effect of Targeting Upper Normal Serum Magnesium Levels on Norepinephrine Requirements in Septic Shock Patients), which is not on this map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Targeting Upper Normal Serum Magnesium Levels on Norepinephrine Requirements in Septic Shock Patients: a Randomized Controlled Trial.
Who cites it
44 citing papers in PubMed, 119 citations in OpenAlex.
- Pre-emptive hydrocortisone therapy in early septic shock: a double-blind, allocation-concealed, pilot randomized controlled trial.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2025Trial
- Influence of liberal versus conservative oxygen therapies on the hemodynamic parameters of mechanically ventilated patients with sepsis: a randomized clinical trial.BMC anesthesiology · 2024Trial
- Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2026.Intensive care medicine · 2026Article
- Early Norepinephrine Attenuates Fluid-Associated Albumin Decline in Sepsis: A Prospective Longitudinal Study.Journal of clinical medicine · 2026Article
- Early inotropic support without fluid bolusWorld journal of clinical pediatrics · 2026Article
- Sodium ascorbate versus ascorbic acid in sepsis: a narrative review of emerging cardiovascular and neurological benefits.Critical care (London, England) · 2026Review
- Review
- Assessment of Vascular Endothelial Dysfunction in Septic Patients Using Brachial Flow-Mediated Dilation: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2025Review
- Development of an interpretable machine learning model for predicting prolonged hospital stay in patients with acute exacerbation of chronic obstructive pulmonary disease: a retrospective cohort study.BMC medical informatics and decision making · 2025Article
- A Novel Approach to Early Personalized Hemodynamic Resuscitation: Non-Invasive Peripheral Photoplethysmography for Identifying Predominant Vasodilatory Shock in Sepsis.Acta anaesthesiologica Scandinavica · 2025Article
- ChronoSynthNet: a dual-task deep learning model development and validation study for predicting real-time norepinephrine dosage and the early detection of hypotension in patients with septic shock.Cardiovascular diagnosis and therapy · 2025Article
- Association between sleep disorder and delirium in adult patients undergoing cardiac surgery: a retrospective cohort study.BMC anesthesiology · 2025Article
- Vasopressin and its analogues in patients with septic shock: holy Grail or unfulfilled promise?Critical care (London, England) · 2025Review
- Biomarkers to guide sepsis management.Annals of intensive care · 2025Review
- Hemoperfusion with Seraph-100 in septic patients removes pathogens and improves clinical outcomes.Scientific reports · 2025Article
- Hemodynamic effects of adjunct arginine vasopressin to norepinephrine in septic shock: insights from a prospective multicenter registry study.Annals of intensive care · 2025Article
- Effect of timing of norepinephrine administration on prognosis of patients with septic shock: A prospective cohort study.Journal of intensive medicine · 2025Article
- Application of causal forests to randomised controlled trial data to identify heterogeneous treatment effects: a case study.BMC medical research methodology · 2025Article
- Case Report: Complete recovery of a patient with occult septic shock following supranormal vasopressor and inotrope therapy informed by the novel 'pressure field method' for managing hemodynamics.Frontiers in medicine · 2025Article
- Septic Shock Requiring Three Vasopressors: Patient Demographics and Outcomes.Critical care explorations · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In addition to fluid resuscitation, the vasopressor therapy is a fundamental treatment of septic shock-induced hypotension as it aims at correcting the vascular tone depression and then at improving organ perfusion pressure. Experts' recommendations currently position norepinephrine (NE) as the first-line vasopressor in septic shock. Vasopressin and its analogues are only second-line vasopressors as strong recent evidence suggests no benefit of their early administration in spite of promising preliminary data. Early administration of NE may allow achieving the initial mean arterial pressure (MAP) target faster and reducing the risk of fluid overload. The diastolic arterial pressure (DAP) as a marker of vascular tone, helps identifying the patients who need NE urgently. Available data suggest a MAP of 65 mmHg as the initial target but a more individualized approach is often required depending on several factors such as history of chronic hypertension or value of central venous pressure (CVP). In cases of refractory hypotension, increasing NE up to doses ≥1 µg/kg/min could be an option. However, current experts' guidelines suggest to combine NE with other vasopressors such as vasopressin, with the intent to rising the MAP to target or to decrease the NE dosage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.